Commissioning endotoxin testing services: why inhibition and enhancement testing comes before any sample, what is bioburden testing as distinct from it and how bioburden testing answers a different question about the same product, and what the report has to state for a release decision to rest on it

Commissioning the work

1. Do the inhibition and enhancement study first. Before any routine testing, the laboratory has to show your product does not interfere with the assay, by spiking a known amount of endotoxin into it and recovering it within the required window. That validation is product-specific and it takes time nobody schedules.
2. Fix the dilution and the endotoxin limit. The limit follows from the dose and the route of administration, and the maximum valid dilution follows from the limit and the assay sensitivity. Those two numbers define the test, and they belong in the request rather than being derived by the laboratory from assumptions.
3. Understand what bioburden counts. Bioburden is the viable organism count before sterilisation and it drives the sterilisation process design. It is not a sterility test and it is not endotoxin; a product can be low bioburden and high endotoxin, because killing the organisms leaves their cell wall material behind.
4. Use depyrogenated glassware and controls throughout. Endotoxin is everywhere and survives autoclaving, so glassware is depyrogenated by dry heat and every run carries a positive product control. A negative result from a contaminated workflow is not a negative result.
5. Ask what the report will state. The method, the sample dilution, the endotoxin limit applied, the standard curve and its acceptance, the positive product control recovery, and the result with its units. A number without the recovery figure cannot support a release decision.

Choosing between the assay formats

Gel clot is simple, robust and semi-quantitative; kinetic turbidimetric and chromogenic formats give a number across a range and need more instrumentation and more validation. Recombinant reagent formats avoid the animal-derived source and require their own equivalence work.

Which format a laboratory runs decides turnaround and cost per sample, and switching format for a product already validated is a revalidation rather than a change of supplier.

Sampling and handling

Endotoxin adsorbs to some container surfaces and is unevenly distributed, so how and where the sample was taken matters. Use depyrogenated containers, agree the sampling plan, and record it with the result.

For devices and components, the extraction method is part of the test and has to be specified. Two laboratories extracting differently will report different numbers from the same item and both will be right.

Common questions

What is inhibition and enhancement testing?

A product-specific validation showing your sample does not interfere with the endotoxin assay, done by spiking a known amount into the product and recovering it within the required window. It comes before routine testing rather than alongside it.

Is bioburden testing the same as sterility testing?

No. Bioburden counts viable organisms in a product before sterilisation and informs the sterilisation process. Sterility testing asks whether a sterilised product shows growth. They answer different questions at different points.

Can a product be sterile and still fail endotoxin?

Yes, and that is the point of testing both. Sterilisation kills organisms and leaves their cell wall material, which is pyrogenic, so a sterile product can carry an endotoxin load well above its limit.

What sets the endotoxin limit?

The dose and the route of administration, through the standard formula in the compendial method. It is a property of the product's use rather than of the product itself, which is why the request has to state the intended dose.

Browse by service class

• Compare Gene synthesis on advertised prices